The IL-1β inhibitors, such as anakinra, canakinumab, and the IL-1 receptor type I fusion protein rilonacept, induce significant clinical response in CAPS, indicating that signal transduction through the IL-1 receptor is crucial for the pathogenesis of CAPS (9, 10). The gene discussed is IL1B; the disease is cryopyrin-associated periodic syndrome.